SCHEMBL30134086

SCHEMBL30134086

CC(O)c1ccc(F)cc1C(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ PDE2A O00408 2/20 0.38
▸ CES2 O00748 2/20 0.37
▸ CES1 P23141 2/20 0.37
▸ KCNH2 Q12809 3/20 0.36
▸ PSEN1 P49768 2/20 0.33
▸ PSEN2 P49810 2/20 0.33
▸ APH1B Q8WW43 2/20 0.33
▸ NCSTN Q92542 2/20 0.33
▸ APH1A Q96BI3 2/20 0.33
▸ PSENEN Q9NZ42 2/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ METAP2 P50579 1/20 0.33
▸ HTR2A P28223 2/20 0.33
▸ HTR2C P28335 2/20 0.33
▸ GCGR P47871 1/20 0.33
▸ CA3 P07451 1/20 0.32
▸ CA6 P23280 1/20 0.32
▸ CA5A P35218 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20818058 1.00 MEN1 (0.40) MEN1KMT2APDE2ACES2CES1
SCHEMBL17310040 0.92 MEN1 (0.40) MEN1KMT2APDE2ACES2CES1
SCHEMBL10039364 0.83 RECQL (0.36) PDE2ACES2CES1KCNH2PSEN1
SCHEMBL24869041 0.81 MEN1 (0.41) MEN1KMT2APDE2ACES2CES1
SCHEMBL30133933 0.80 MEN1 (0.35) MEN1KMT2APDE2ACES2CES1
SCHEMBL20817934 0.79 PSEN1 (0.37) CES2CES1KCNH2PSEN1PSEN2
SCHEMBL31574267 0.79 PSEN1 (0.37) CES2CES1KCNH2PSEN1PSEN2
SCHEMBL15954389 0.79 PDE2A (0.43) PDE2APSEN1PSEN2APH1BNCSTN
SCHEMBL31574281 0.79 PDE2A (0.43) PDE2APSEN1PSEN2APH1BNCSTN
SCHEMBL30134000 0.79 MEN1 (0.37) MEN1KMT2APDE2ACES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125378-A2 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2026-05-07 — — US disclosed
EP-4658650-A1 HETEROCYCLIC COMPOUNDS Beone Medicines I GmbH (CH) 2025-12-10 — — EP disclosed
EP-4658655-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES Beone Medicines I GmbH (CH) 2025-12-10 — — EP disclosed
US-20250353858-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEONE MEDICINES I GMBH (CH) 2025-11-20 — — US disclosed
US-20250353846-A1 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2025-11-20 — — US disclosed
CN-113939295-B Pyridazinones and methods of use thereof 金翅雀生物公司 2025-05-16 — — CN disclosed
CN-119119033-A Pyrazolopyridone compounds 百济神州有限公司 2024-12-13 — — CN disclosed
EP-4457224-A1 HETEROCYCLIC COMPOUNDS BeiGene Switzerland GmbH (CH) 2024-11-06 — — EP disclosed
US-20240327417-A1 HETEROCYCLIC COMPOUNDS BEIGENE SWITZERLAND GMBH (CH) 2024-10-03 — — US disclosed
US-20240300951-A1 Pyrazolopyridinone Compounds BEIGENE LTD. (KY) 2024-09-12 — — US disclosed
US-20240270751-A1 Pyrazolopyridinone Compounds BEIGENE LTD. (KY) 2024-08-15 — — US disclosed
WO-2024160277-A1 HETEROCYCLIC COMPOUNDS BEIGENE, LTD. (KY) 2024-08-08 — — WO disclosed
WO-2024160278-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEIGENE, LTD. (KY) 2024-08-08 — — WO disclosed
CN-118451073-A Heterocyclic compounds 百济神州有限公司 2024-08-06 — — CN disclosed
EP-4380936-A1 PYRAZOLOPYRIDINONE COMPOUNDS BeiGene, Ltd. (KY) 2024-06-12 — — EP disclosed
CN-117836296-A Pyrazolopyridone compounds 百济神州有限公司 2024-04-05 — — CN disclosed
WO-2023125681-A1 HETEROCYCLIC COMPOUNDS BEIGENE, LTD. (KY) 2023-07-06 — — WO disclosed
WO-2023011456-A1 PYRAZOLOPYRIDINONE COMPOUNDS BEIGENE, LTD. (KY) 2023-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125378-A2 Heterocyclic Compounds NFATC1, CD4, MALT1 MEN1 3179/4885KMT2A 3652/4885PDE2A 3817/4885
US-20250353858-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES DGKG, DGKK, DGKA MEN1 3805/4885KMT2A 2337/4885PDE2A 1596/4885
US-20240327417-A1 HETEROCYCLIC COMPOUNDS NFATC1, CD4, ACIN1 MEN1 3612/4885KMT2A 2438/4885PDE2A 2623/4885
US-20250353846-A1 Heterocyclic Compounds NFATC1, CD4, ACIN1 MEN1 3612/4885KMT2A 2438/4885PDE2A 2623/4885
US-20240300951-A1 Pyrazolopyridinone Compounds NFATC1, CD4, PBK MEN1 3837/4885KMT2A 2627/4885PDE2A 986/4885
US-20240270751-A1 Pyrazolopyridinone Compounds NFATC1, CD4, PBK MEN1 3837/4885KMT2A 2627/4885PDE2A 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback